Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) have earned an average broker rating score of 3.67 (Sell) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong sell rating and two have assigned a hold rating to the company.
Brokers have set a one year consensus price target of $1.12 for the company and are expecting that the company will post ($0.17) EPS for the current quarter, according to Zacks. Zacks has also assigned Galectin Therapeutics an industry rank of 88 out of 265 based on the ratings given to related companies.
Several equities research analysts have issued reports on the stock. FBR & Co restated a “market perform” rating and set a $2.00 price objective on shares of Galectin Therapeutics in a research report on Monday, February 6th. Zacks Investment Research downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, January 16th.
Several large investors have recently added to or reduced their stakes in GALT. Advisor Group Inc. increased its stake in Galectin Therapeutics by 3.8% in the third quarter. Advisor Group Inc. now owns 413,125 shares of the company’s stock worth $467,000 after buying an additional 15,200 shares during the last quarter. Benchmark Capital Advisors increased its stake in Galectin Therapeutics by 98.3% in the third quarter. Benchmark Capital Advisors now owns 118,200 shares of the company’s stock worth $134,000 after buying an additional 58,600 shares during the last quarter. Finally, Courage Capital Management LLC acquired a new stake in Galectin Therapeutics during the third quarter worth $147,000. Institutional investors own 10.01% of the company’s stock.
Shares of Galectin Therapeutics (NASDAQ:GALT) opened at 1.80 on Wednesday. Galectin Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.05. The company’s market capitalization is $52.91 million. The company’s 50-day moving average price is $1.08 and its 200-day moving average price is $1.25.
This story was first posted by sleekmoney and is owned by of sleekmoney. If you are reading this story on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The original version of this story can be viewed at http://sleekmoney.com/brokerages-anticipate-galectin-therapeutics-inc-galt-to-announce-0-17-earnings-per-share/1661766.html.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/brokerages-anticipate-galectin-therapeutics-inc-galt-to-announce-0-17-earnings-per-share/1661766.html
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.